// App-Quantinova.ai

P424 : Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations

Researchers

Presenter

  • Alice, H

Principal Investigators

  • Gemma, B

  • Selinger, C.P

Medical Centers

  • St. James' University Hospital, Gastroenterology, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved